Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity

Hyun Seok Hong, Izumi Maezawa, Nianhuan Yao, Bailing Xu, Ruben Diaz-Avalos, Sandeep Rana, Duy H. Hua, R. Holland Cheng, Kit Lam, Lee-Way Jin

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The discovery of small molecule inhibitors of cytotoxicity induced by amyloid-β (Aβ) oligomers, either applied extracellularly or accumulated intraneuronally, is an important goal of drug development for Alzheimer's disease (AD), but has been limited by the lack of efficient screening methods. Here we describe our approach using two cell-based methods. The first method takes advantage of the unique ability of extracellularly applied Aβ oligomers to rapidly induce the exocytosis of formazan formed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). We employed a short protocol to quantify this toxicity, and quickly identified two novel inhibitors, code-named CP2 and A5, from two compound libraries. A second independent screen of the same libraries using our previously published MC65 protection assay, which identifies inhibitors of toxicity related to intracellular Aβ oligomers, also selected the same two leads, suggesting that both assays select for the same anti-Aβ oligomer properties displayed by these compounds. We further demonstrated that A5 attenuated the progressive aggregation of existing Aβ oligomers, reduced the level of intracellular Aβ oligomers, and prevented the Aβ oligomer-induced death of primary cortical neurons, effects similar to those demonstrated by CP2. Our results suggest that, when combined, the two methods would generate fewer false results and give a high likelihood of identifying leads that show promises in ameliorating Aβ oligomer-induced toxicities within both intraneuronal and extracellular sites. Both assays are simple, suitable for rapid screening of a large number of medicinal libraries, and amenable for automation.

Original languageEnglish (US)
Pages (from-to)223-234
Number of pages12
JournalBrain Research
Volume1130
Issue number1
DOIs
StatePublished - Jan 26 2007

Fingerprint

Exocytosis
Library Automation
Libraries
Formazans
Aptitude
Amyloid
Alzheimer Disease
Neurons
carbazole
MTT formazan
Pharmaceutical Preparations

Keywords

  • Aggregation
  • Alzheimer's disease
  • Amyloid-β
  • Oligomer
  • Small molecule
  • Toxicity

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity. / Hong, Hyun Seok; Maezawa, Izumi; Yao, Nianhuan; Xu, Bailing; Diaz-Avalos, Ruben; Rana, Sandeep; Hua, Duy H.; Cheng, R. Holland; Lam, Kit; Jin, Lee-Way.

In: Brain Research, Vol. 1130, No. 1, 26.01.2007, p. 223-234.

Research output: Contribution to journalArticle

Hong, Hyun Seok ; Maezawa, Izumi ; Yao, Nianhuan ; Xu, Bailing ; Diaz-Avalos, Ruben ; Rana, Sandeep ; Hua, Duy H. ; Cheng, R. Holland ; Lam, Kit ; Jin, Lee-Way. / Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity. In: Brain Research. 2007 ; Vol. 1130, No. 1. pp. 223-234.
@article{e42f14286117469fb63f357b9da266e6,
title = "Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity",
abstract = "The discovery of small molecule inhibitors of cytotoxicity induced by amyloid-β (Aβ) oligomers, either applied extracellularly or accumulated intraneuronally, is an important goal of drug development for Alzheimer's disease (AD), but has been limited by the lack of efficient screening methods. Here we describe our approach using two cell-based methods. The first method takes advantage of the unique ability of extracellularly applied Aβ oligomers to rapidly induce the exocytosis of formazan formed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). We employed a short protocol to quantify this toxicity, and quickly identified two novel inhibitors, code-named CP2 and A5, from two compound libraries. A second independent screen of the same libraries using our previously published MC65 protection assay, which identifies inhibitors of toxicity related to intracellular Aβ oligomers, also selected the same two leads, suggesting that both assays select for the same anti-Aβ oligomer properties displayed by these compounds. We further demonstrated that A5 attenuated the progressive aggregation of existing Aβ oligomers, reduced the level of intracellular Aβ oligomers, and prevented the Aβ oligomer-induced death of primary cortical neurons, effects similar to those demonstrated by CP2. Our results suggest that, when combined, the two methods would generate fewer false results and give a high likelihood of identifying leads that show promises in ameliorating Aβ oligomer-induced toxicities within both intraneuronal and extracellular sites. Both assays are simple, suitable for rapid screening of a large number of medicinal libraries, and amenable for automation.",
keywords = "Aggregation, Alzheimer's disease, Amyloid-β, Oligomer, Small molecule, Toxicity",
author = "Hong, {Hyun Seok} and Izumi Maezawa and Nianhuan Yao and Bailing Xu and Ruben Diaz-Avalos and Sandeep Rana and Hua, {Duy H.} and Cheng, {R. Holland} and Kit Lam and Lee-Way Jin",
year = "2007",
month = "1",
day = "26",
doi = "10.1016/j.brainres.2006.10.093",
language = "English (US)",
volume = "1130",
pages = "223--234",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity

AU - Hong, Hyun Seok

AU - Maezawa, Izumi

AU - Yao, Nianhuan

AU - Xu, Bailing

AU - Diaz-Avalos, Ruben

AU - Rana, Sandeep

AU - Hua, Duy H.

AU - Cheng, R. Holland

AU - Lam, Kit

AU - Jin, Lee-Way

PY - 2007/1/26

Y1 - 2007/1/26

N2 - The discovery of small molecule inhibitors of cytotoxicity induced by amyloid-β (Aβ) oligomers, either applied extracellularly or accumulated intraneuronally, is an important goal of drug development for Alzheimer's disease (AD), but has been limited by the lack of efficient screening methods. Here we describe our approach using two cell-based methods. The first method takes advantage of the unique ability of extracellularly applied Aβ oligomers to rapidly induce the exocytosis of formazan formed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). We employed a short protocol to quantify this toxicity, and quickly identified two novel inhibitors, code-named CP2 and A5, from two compound libraries. A second independent screen of the same libraries using our previously published MC65 protection assay, which identifies inhibitors of toxicity related to intracellular Aβ oligomers, also selected the same two leads, suggesting that both assays select for the same anti-Aβ oligomer properties displayed by these compounds. We further demonstrated that A5 attenuated the progressive aggregation of existing Aβ oligomers, reduced the level of intracellular Aβ oligomers, and prevented the Aβ oligomer-induced death of primary cortical neurons, effects similar to those demonstrated by CP2. Our results suggest that, when combined, the two methods would generate fewer false results and give a high likelihood of identifying leads that show promises in ameliorating Aβ oligomer-induced toxicities within both intraneuronal and extracellular sites. Both assays are simple, suitable for rapid screening of a large number of medicinal libraries, and amenable for automation.

AB - The discovery of small molecule inhibitors of cytotoxicity induced by amyloid-β (Aβ) oligomers, either applied extracellularly or accumulated intraneuronally, is an important goal of drug development for Alzheimer's disease (AD), but has been limited by the lack of efficient screening methods. Here we describe our approach using two cell-based methods. The first method takes advantage of the unique ability of extracellularly applied Aβ oligomers to rapidly induce the exocytosis of formazan formed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). We employed a short protocol to quantify this toxicity, and quickly identified two novel inhibitors, code-named CP2 and A5, from two compound libraries. A second independent screen of the same libraries using our previously published MC65 protection assay, which identifies inhibitors of toxicity related to intracellular Aβ oligomers, also selected the same two leads, suggesting that both assays select for the same anti-Aβ oligomer properties displayed by these compounds. We further demonstrated that A5 attenuated the progressive aggregation of existing Aβ oligomers, reduced the level of intracellular Aβ oligomers, and prevented the Aβ oligomer-induced death of primary cortical neurons, effects similar to those demonstrated by CP2. Our results suggest that, when combined, the two methods would generate fewer false results and give a high likelihood of identifying leads that show promises in ameliorating Aβ oligomer-induced toxicities within both intraneuronal and extracellular sites. Both assays are simple, suitable for rapid screening of a large number of medicinal libraries, and amenable for automation.

KW - Aggregation

KW - Alzheimer's disease

KW - Amyloid-β

KW - Oligomer

KW - Small molecule

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=33846174301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846174301&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2006.10.093

DO - 10.1016/j.brainres.2006.10.093

M3 - Article

C2 - 17157826

AN - SCOPUS:33846174301

VL - 1130

SP - 223

EP - 234

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -